secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2024-07-18T23:59:59+00:00
Accession:  0001193125-24-181093
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health appoints Dr. Manuel Hidalgo Medina to board effective July 17
-----------------------------------------------------------------------------

- Board increased to nine seats; Dr. Hidalgo appointed as Class II director, term expiring at 2026 annual meeting.
- Dr. Hidalgo is Chief of Hematology/Medical Oncology at Weill Cornell Medicine and also serves on Bristol-Myers Squibb's board.
- Received standard non-employee director compensation: stock option and RSU awards each valued at $362,500, vesting over four years.
- Appointed to the nominating and corporate governance committee of the board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000119312524181093/0001193125-24-181093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000119312524181093/d771601d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-181093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer